February 18, 2024
Published by TDP on February 18, 2024
Categories

Is it Safe for Pregnant Women to Eat Imitation Crab? What You Need to Know

When it comes to the topic of whether it is safe for pregnant women to eat imitation crab, there are several considerations to take into account. Understanding what imitation crab is, the ingredients it contains, and the potential benefits and risks of consuming this seafood alternative is crucial for expectant mothers.
Do you like it?41
0 Read more
February 13, 2024
Published by TDP on February 13, 2024
Categories

Understanding Palbociclib (Ibrance) in Advanced Breast Cancer Treatment

Palbociclib (Ibrance) is a CDK4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC).
Do you like it?91
0 Read more
February 12, 2024
Published by TDP on February 12, 2024
Categories

Prophylactic Mitomycin-C Application for Haze Prevention after Photorefractive Keratectomy in Myopia: A Systematic Review

This systematic review explores the efficacy of prophylactic Mitomycin-C in preventing haze formation following Photorefractive Keratectomy for the treatment of myopia. The analysis compiles results from various studies to provide a comprehensive understanding of the effectiveness and safety of Mitomycin-C application in refractive surgery.
Do you like it?13
0 Read more
February 7, 2024
Published by TDP on February 7, 2024
Categories

Unlocking the Potential of Enhertu: A Revolutionary Advance in Targeted Cancer Therapy

The development of Enhertu represents a significant advancement in targeted cancer therapy, offering new hope for patients with limited treatment options. Enhertu, also known as trastuzumab deruxtecan, is an innovative antibody-drug conjugate (ADC) designed to target HER2-positive cancers, which are associated with aggressive growth and poor prognosis in various cancer types, including breast and gastric cancers
Do you like it?34
0 Read more
January 24, 2024
Published by TDP on January 24, 2024
Categories

New Findings on Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) is a rare, progressive, and often fatal genetic disease caused by mutations in the transthyretin (TTR) gene. It results in the accumulation of amyloid fibrils in the nerves, heart, and other organs, leading to symptoms such as polyneuropathy and cardiomyopathy, as well as other serious complications.
Do you like it?52
0 Read more
January 22, 2024
Published by TDP on January 22, 2024
Categories

Pluvicto: Most Asked Questions

"for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."
Do you like it?55
0 Read more
January 19, 2024
Published by TDP on January 19, 2024
Categories

Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
Do you like it?53
0 Read more
December 16, 2023
Published by TDP on December 16, 2023
Categories

Navigating Complex Moral Choices in Obstetrics: The Intersection of Maternal Cancer and Pregnancy

During her rotation in obstetrics and gynecology, a resident encountered a 28-year-old pregnant woman at 13 weeks gestational age, who already has three healthy children. I […]
Do you like it?85
0 Read more
Prev page
1234...53
Next page
Comparing VTE Prophylaxis Medications for Deep Vein Thrombosis & Pulmonary Embolism
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more